CXCL1-overexpressing cancer-associated fibroblasts stimulate hepatocellular carcinoma progression via neutrophil recruitment, NET formation, and immune suppression
Cancer Immunology, Immunotherapy · 2026
DOI: 10.1007/s00262-026-04304-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Bin Bi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation OncologySichuan Clinical Research Center for CancerSichuan Cancer Center, Affiliated Cancer Hospital of University of Electro…. Hauptthemen laut MEDLINE: Chemokine CXCL1, Liver Neoplasms, Carcinoma, Hepatocellular, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with a prognosis often limited by an immunosuppressive tumor microenvironment (TME). While cancer-associated fibroblasts (CAFs) are known to influence tumor progression, the specific mechanisms by which they modulate immune cell recruitment and function remain poorly defined. This study investigates how CAF-derived CXCL1 orchestrates a pro-tumorigenic stroma through neutrophil manipulation. METHODS: The study employed in vitro co-culture systems and in vivo murine models to evaluate the impact of CXCL1-overexpressing CAFs on HCC progression. The signaling mechanisms were assessed using CXCR2 and STAT3 inhibitors, while immune surveillance was monitored via CD8+ T cell activity and natural killer (NK) cell infiltration assays. RESULT: CXCL1 secreted by CAFs was found to activate neutrophils via the CXCR2-STAT3 signaling axis. This activation induces the formation of neutrophil extracellular traps (NETs), which directly facilitate tumor proliferation and metastasis. Furthermore, CXCL1-driven NETs established a potent immunosuppressive TME by significantly impairing CD8+ T cell activity and reducing NK cell infiltration. Conversely, neutralizing CXCL1 or inhibiting the CXCR2-STAT3 pathway successfully suppressed NET formation, restored anti-tumor immune cell functionality, and mitigated tumor growth. CONCLUSIONS: The CXCL1-CXCR2-STAT3 axis is a critical driver of stromal-immune interactions in HCC. By mediating neutrophil recruitment and NET-driven immune evasion, CAFs create a permissive environment for tumor escalation. Targeting this signaling pathway represents a promising therapeutic strategy to disrupt pro-tumorigenic neutrophil mechanisms and reinvigorate the host's anti-tumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation OncologySichuan Clinical Research Center for CancerSichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Sichuan Cancer Hospital & Institu…
- Department of Gynecological Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technolog…
- Department of Neurology, Chengdu Third Peoples Hospital, Chengdu, 610000, Sichuan, China.
Zitieren
APA
Bi, B., Tang, L., Liang, R., Wu, H., Huang, Q., & Pan, L. (2026). CXCL1-overexpressing cancer-associated fibroblasts stimulate hepatocellular carcinoma progression via neutrophil recruitment, NET formation, and immune suppression. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04304-3
Vancouver
Bi B, Tang L, Liang R, Wu H, Huang Q, Pan L. CXCL1-overexpressing cancer-associated fibroblasts stimulate hepatocellular carcinoma progression via neutrophil recruitment, NET formation, and immune suppression. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04304-3
BibTeX
@article{Bi2026,
author = {Bi, Bin and Tang, Liqin and Liang, Ranxi and Wu, Haijing and Huang, Qilan and Pan, Li},
title = {CXCL1-overexpressing cancer-associated fibroblasts stimulate hepatocellular carcinoma progression via neutrophil recruitment, NET formation, and immune suppression},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04304-3}
}
EUVIMED